weight infants in the United States during the 1970s was due an effect could be operative in humans. Pregnenolone, derived largely to a decrease in term, small for gestational age infants (1).
from the placenta, is converted to dehydroepiandrosterone sulThis suggests that intrauterine growth-retardated infants repre-fate in the fetal adrenal. Dehydroepiandrosterone sulfate is subsent the category of low birth weight infants most amenable to sequently converted to estradiol-176 and estrone in the placenta. change, that which we could affect even more dramatically if we These compounds in turn stimulate the maternal renin-angiotenunderstood the pathogenesis more thoroughly.
sin-aldosterone system causing retention of extracellular fluid, I hope to raise several conceptual issues and questions regard-thereby increasing maternal plasma volume. Chorionic somatoing fetal growth for which we do not yet have complete answers, mammotropin stimulates maternal erythropoiesis and increases hoping to stimulate further research in this area. It should also red cell mass. The resulting augmentation of blood volume be emphasized that there may be a commonality between growth results in increased cardiac output, increased uteroplacental and differentiation or function-that factors impairing fetal blood flow, and transfer of flow-dependent substrates such as growth may also interfere with normal cell and organismal amino acids to the fetus. In this interaction the fetus is far from differentiation. First, let us consider the relationship of placental a passive participant, but rather has some control of its own blood flow to fetal growth. There is a strong correlation among destiny. One can envision fetal factors other than adrenal steroid uteroplacental blood flow, placental size, and fetal size. In hu-production that might be operative in the regulation of placental mans, placental weights are greatest in large for gestational age function. Studies to test these hypotheses should be undertaken. infants and lowest in small for gestional age infants (2). Saintonge A second issue of interest is the different patterns of fetal and Rosso (3) observed a reduction in placental blood flow in growth at different stages of gestation. The late phase of gestation spontaneously growth-retarded fetuses and increased flow in is devoted largely to fetal energy storage, in the form of fat and spontaneously macrosomic fetuses. Importantly, Myers et ul. (4) carbohydrate, as well as to biochemical "fine-tuning" in prepastudying this same phenomenon in chronically catheterized ration for extrauterine adaptation. Earlier in gestation cell prolifguinea pigs removed from the surgical stresses known to influ-eration and accretion of protein are the dominant features of ence metabolism and cardiovascular function, found a similar fetal growth. This could mean that humoral regulation of fetal relationship, viz, a strong correlation between placental blood growth varies at different stages of gestation. The humoral reguflow and spontaneous fetal weight.
lation of growth in the fetus differs significantly from postnatal growth regulation. Jost (8) (10) in the rat show that near term body weight and plasma insulin correlated positively, while weight and plasma growth hormone concentration correlated negatively. Of course, such associations do not prove a causal role for insulin in fetal growth. Therefore, various researchers have examined the effects of insulin administration on fetal growth. Picon (1 1) injected rat fetuses with large daily doses of insulin for 3 days late in gestation and found, relative to controls, increased weight, nitrogen content, and lipid content at term. Susa et al. (12) infused insulin continuously to rhesus monkey fetuses during the latter part of pregnancy and reported a 34% increase in body weight versus age-matched controls, with increased size of the heart, liver, spleen, and, most dramatically, the placenta. Although other studies employing different species have produced different results, there is now a considerable body of data sugesting an anabolic role for insulin in the fetus.
Thus, we might ask 1) How is insulin secretion regulated in the fetus? and 2) how might insulin act in modulating fetal metabolism and growth? Studies in the chronically catheterized fetal sheep indicate that plasma glucose and insulin concentrations correlate strongly (1 3). Glucose is maximally stimulatory to fetal insulin release at quite low concentrations, but the slope of the dose-response curve is identical in fetal and adult animals. Inhibition of insulin release by adrenergic mechanisms is well developed from early gestation in the fetal sheep (14) . Since catecholamines play an important role in mediating the response of the fetus to hypoxia, catecholamine inhibition of insulin release may influence growth during chronic hypoxia. Thus, changes in glucose or oxygen supply across the placenta, modulating fetal insulin secretion, theoretically could allow the fetus to participate in regulating its own metabolic processes.
What are the metabolic actions of insulin in the fetus? In postnatal animals insulin is known to have diverse anabolic actions, including its well-known effects on glucose uptake and lipogenesis, but insulin also exerts effects on amino acid and protein metabolism, such as increased amino acid uptake, stimulation of protein synthesis in some tissues, and inhibition of protein degradation in many tissues. In the fetus we know much less about insulin's actions, but some data are available. For example, Simmons et al. (15) have demonstrated that insulin infusion into fetal sheep late in gestation results in increased umbilical uptake of glucose and increased fetal glucose utilization. However, these effects of insulin on carbohydrate metabolism, as well as those on lipid metabolism, occur only late in gestation.
Much less work has been conducted on other potential actions of insulin which might be important earlier in gestation, such as cellular proliferation and protein turnover. Insulin is known to promote DNA synthesis and cell proliferation in a number of tissue culture systems, including fibroblasts from chick, mouse, and rat embryos. Insulin stimulates amino acid uptake by chick embryo heart as early as 5 days, whereas glucose transport is not sensitive to insulin until 7-10 days of incubation (16) . Sperling et al. (17) have presented evidence that amino acid uptake by isolated fetal rat hepatocytes is stimulated by insulin, while I4C-glucose incorporation into glycogen is not. This suggests separate insulin-mediated post receptor events which mature independently. It seems reasonable to postulate that the growth-promoting action of insulin in the fetus may be related to increased cell proliferation and protein accretion early in gestation, at least in some tissues, while late in gestation the major effects of insulin relate to energy storage. Further studies of insulin action in early and mid-gestation should help test this hypothesis.
Let us now probe the potential role for somatomedins and other growth factors in the regulation fetal growth and, as a corollary, whether combinations of growth factors acting in concert might promote optimal fetal growth. Although the evidence for such a role for somatomedins is indirect, it becomes progressively more compelling. Unlike specific growth factors, such as nerve growth factor, which have quite specialized target cell populations, somatomedins appear to influence the growth of many types of cells. Somatomedins stimulate mitosis of many fetal cell types in organ or tissue culture.
Moreover, numerous fetal tissues contain specific somatomedin binding or receptor sites. These include placenta, brain, monocytes, and other tissues. D'Ercole et al. (18) have shown that specific binding of somatomedin-C to the fetal side of the pig placenta increases as gestation advances, suggesting another mechanism whereby fetal factors may influence placental and, indirectly, maternal metabolism. Rosenfeld et al. (19) have reported that specific binding of somatomedin-C to circulating mononuclear cells in human cord blood is greater than to adult mononuclear cells. Thus, there may be increased sensitivity of fetal tissues to somatomedins.
Several fetal tissues have been shown to elaborate somatomedins. D'Ercole et al. (20) have studied somatomedin synthesis by explants of fetal mouse tissues. Somatomedin-C content in media from organ explants of the 17-day fetus increased considerably during 3 days in culture for all tissues assayed except placenta.
In humans, somatomedin concentrations in fetal blood correlate with size at birth (1 8, 2 1). The concentration of multiplication-stimulating activity, the rat homologue of IGF-11, is very high in fetal rat serum compared to postnatal concentrations (22) . However, studies in humans reveal lower levels of both major somatomedin types (IGF-I and IGF-11) in fetal than in adult blood. This finding would not seem to support the proposed growth-promoting role for somatomedins in the human fetus, but several arguments can be adduced to explain this apparent incongruity. There is evidence, already alluded to, for increased sensitivity of tissues of the fetus to somatomedins. In addition, the fact that somatomedins are synthesized by numerous fetal tissues suggests the possibility that they are operating by paracrine or autocrine mechanisms rather than bv classical endocrine mechanisms, i.e. that fetal tissues are elabdrating somatomedins which act on nearby cells or, in fact, which promote their own growth. If this is true, serum concentrations of these agents are less relevant.
Parenthetically, Roth et al. (23) have recently found that peptide molecules previously considered to be purely endocrine, and originating in specialized unique cell types, such as insulin and ACTH, are present in unicellular and primitive multicellular organisms. They propose that these intercellular communicators began evolutionally and embryologically as local tissue factors acting first as autocrine secretions, subsequently in a paracrine manner on neighboring cells; and, finally, with morphological and developmental advances, some of the messenger molecules developed into humoral agents. It is reasonable to presume that somatomedins in fetal life progress through this same sequence, from autocrine to paracrine to endocrine functions-another example of ontogeny recapitulating phylogeny.
There also may be a role in fetal growth for the numerous other polypeptide growth factors which have been identified, and there may be cooperative interactions among these factors. Kaplowitz et a/. (24) have illustrated how some of these growth factors may interact with their studies of the growth of embryonic mouse limb bud mesenchyme. Several factors stimulate mitogenesis of limb bud cultures when studied individually, such as epidermal growth factor, fibroblast growth factor, insulin, multiplication-stimulating activity, and somatomedin-C. Yet, maximal growth requires the presence simultaneously of several factors: conditioned medium from liver explants, epidermal growth factor, fibroblast growth factor, and either insulin or somatomedin-C.
That multiple growth factors are required for optimal rates of cell division in such a system is not surprising in view of studies by Stiles et a/. (25) on the effects of growth factors on regulation of the cell cycle. These investigators identified at least two control points in the cell cycle for specific growth factors. The growth cycle of exponentially multiplying cells is divided into four discrete phases: G I , the period between mitosis and DNA synthesis; S, the period of DNA synthesis; G2, the period between DNA synthesis and mitosis; and M. mitosis. When cell confluency is reached, replicative DNA synthesis and cell division are arrested. This quiescent phase is designated Go. Entry back into the S phase requires a combination of growth factors. One type of factor, represented by platelet-derived growth factor or fibroblast growth factor renders cells competent to enter S. These factors in and of themselves will not allow cells to synthesize DNA. The second type of factor, known as a progression factor, allows competent cells to progress through Go and G I and enter the S phase. Somatomedins, as well as epidermal growth factor, are potent progression factors in selected cell types. For the Tlymphocyte. lectins such as concanavalin A serve as competence factors, while the T-cell specific growth factor, interleukin-2, serves as the progression factor. Thus, there may be coordinate control of cell growth by these types of growth factors.
Provocative recent work in the oncogene field prompts one to speculate not only on the mechanisms by which viral oncogenes promote tumorigenesis, but also on the regulation of normal cell growth. Evidence indicates that oncogenes may act to transform normal cells in different ways, e.g. by coding for the synthesis of growth factors such as platelet-derived growth factor, allowing independent proliferation via "autocrine" secretion (26, 27) , or by causing expression of uncontrolled growth factor receptor function (28) . It is not fatuous to speculate that the products of protooncogenes, the normal cellular counterparts of viral oncogenes, are important in the regulation of fetal growth. As cell biology and cancer biology rapidly meld, studies of the control of protooncogene expression may improve our understanding of the regulation of embryonc and fetal growth.
Finally, I wish to emphasize that the accretion of any substance during growth is the result of the net balance between its synthesis and degradation. Thus Kg = Ks -Kd, where Kg represents the fractional growth rate for protein, Ks the fractional rate of synthesis, and Kd the fractional rate of degradation. Studies of protein turnover by Meier et a/. (29) in the fetal sheep show that early in the 3rd trimester both Ks and Kd are high and both decrease as gestation proceeds. The high rates of degradation found in some growing tissues may be necessary for the remodeling which accompanies growth. Our own studies indicate, however, that different fetal tissues have different patterns of protein turnover than those seen in the whole organisms. In vivo determination of protein turnover in the fetal rat shows that Ks is higher and Kd lower in heart and diaphragm during the phase of most rapid growth (day 19) than during a phase of slower growth (day 21), at which time Ks falls and Kd increases (30) . Interestingly, postnatal protein accretion in various tissues of the rat, such as skeletal muscle and liver. occurs by different mechanisms than those operative in fetal life.
Thus, growth in the fetus can be modified by either changes in rates of protein synthesis and/or rates of degradation. Studies of protein degradative mechanisms during fetal life should help our understanding of growth regulation. We now recognize two independent mechanisms for intracellular protein degradation: one cytoplasmic and energy dependent, involved primarily in breakdown of rapidly metabolized proteins; and two lysosomal in location. involved in degradation of proteins with long halflives. The lysosomal process is dependent on calcium ion concentration. Greenberg et ul. (3 1) have shown that calcium does not stimulate proteolysis in fetal striated muscle, and that inhibitors of lysosomal enzymes such as EP 475 do not affect total proteolysis by fetal muscle. T h i~ !~. . _ r observation is not the result of a lack of lysosomal enzyme activity in fetal muscle. Presumably, some step in the process by which autophagic vacuoles fuse with lysosomes is deficient in fetal muscle, and this deserves further experimentation.
To summarize, a variety of maternal, placental, and intrinsic fetal factors are involved in the regulation of fetal growth. There are several recognized, and probably many unrecognized interactions among these components, and there are many unresolved cart versus horse issues in these interactions.
Some quesitons which need to be answered include the following.
1) Are there intrinsic placental factors that modify placental vascular resistance and thus influence placental blood flow, and what factors regulate maternal blood volume expansion?
2) How might fetal hormones and growth factors influence placental growth and/or function and thus affect nutrient delivery to the fetus? We are in need of better markers of placental growth and function to study this question. Weight, DNA, RNA, and protein content of this complex organ are not sufficient. Markers of endothelial surface area, such as factor VIII antigen or angiotensin-converting enzyme, may be more pertinent in future studies of placental growth.
3) What factors control the expression of genes for the fetal polypeptide growth factors? 4) What are the mechanisms of protein degradation in the fetus and how might fetal hormones or growth factors affect this process?
5) How can we better define the interactions of factors contributing to the regulation of fetal growth?
Although developmental physiologists, biochemists, molecular biologists, morphologists, and endocrinologists may each propose critical arbiters of fetal growth, the conceptual issues I have discussed suggest that, at present, there is no unifying simplistic regulator of fetal growth. I hope that the questions I have raised will be of heuristic value for further investigation.
